# Summary of Proposed Legislation
This document outlines a comprehensive U.S. legislative proposal with several key components:
1. **Research Restrictions**:
- Requires certification from Federal research grant recipients that they are not Chinese citizens or participants in Chinese talent programs
- Prohibits employment of Chinese nationals in federally funded research
- Requires institutions receiving Federal assistance to agree not to knowingly employ individuals participating in Chinese talent programs
2. **Foreign Gifts and Contracts Disclosure**:
- Mandates disclosure of foreign gifts/contracts over $50,000 to universities
- Requires public reporting of restricted/conditional gifts/contracts
- Creates a searchable public database of foreign gifts to universities
- Requires institutions to maintain policies regarding foreign gifts to faculty and staff
3. **Investment Restrictions**:
- Restricts tax-exempt organizations from holding investments in "disqualified Chinese companies" (defined as corporations incorporated in China or with significant Chinese government ownership)
- Requires annual reporting on such investments
- Allows limited waivers with public disclosure
4. **Taiwan Policy**:
- Prohibits U.S. government from recognizing PRC claims to sovereignty over Taiwan without Taiwan's consent
- Requires U.S. government to treat Taiwan's democratically elected government as the legitimate representative of the people of Taiwan
- Requires a strategy to protect U.S. businesses from Chinese coercion efforts
5. **Additional Provisions**:
- Requires participants in Chinese talent programs to register as agents of the Chinese government
- Amends economic espionage laws to include education and research
- Mandates disclosure of certain funds received by visa holders
The legislation represents a significant effort to limit Chinese influence in U.S. academic institutions, research, and business sectors while establishing a more robust policy framework regarding Taiwan.
This bill, HR 6860, protects patients with end-stage kidney disease (ESRD) who require dialysis by preventing health insurance plans from discriminating against them. It amends Medicare rules to prohibit plans from treating dialysis coverage differently than other medical services based on a patient’s ESRD diagnosis, need for dialysis, or any other factor. The bill clarifies that plans can still choose which dialysis providers to include in their networks but cannot deny or limit coverage for dialysis services solely because of the patient’s condition. It ensures Medicare remains the secondary payer for these services as intended, without forcing plans to cover specific providers.
HR 6817 imposes a 10% fee on money sent overseas through remittance services (e.g., Western Union, MoneyGram) to fund border security. The fee applies to all international transfers, with U.S. citizens receiving a refundable tax credit equal to the fee paid. Collected fees will fund the new Border Enforcement Trust Fund, which can only be used to hire border agents, build barriers along the U.S.-Mexico border, and operate detention facilities for undocumented immigrants. The bill also includes penalties for evading the fee and restricts foreign aid for countries aiding fee evasion.
HR 6344, the Simon Crosier Act, requires Medicare and Medicaid providers to establish written policies for do-not-resuscitate (DNR) orders involving unemancipated minors (under 18 without legal independence). It mandates that providers must inform at least one parent or legal guardian in person or by phone (with 72 hours of effort) before considering a DNR, allow parents/guardians to refuse consent, and prohibit overriding parental objections to life-sustaining treatment. The bill also requires providers to continue life-sustaining care for 15 days if a parent requests a transfer and explicitly prohibits using disability as the sole basis for DNR decisions. These requirements apply to all Medicare/Medicaid-covered facilities and directly affect minors, their parents, and healthcare providers.
HR 6177 prohibits federal funding from the Department of Health and Human Services (HHS) for researchers involved in studies or experiments involving minors that: (1) affirm a minor's gender identity differing from their sex assigned at birth, (2) provide medical/surgical services to help minors disassociate from their biological sex, or (3) use social interventions for the same purpose. The bill directly affects researchers seeking HHS grants for such studies, requiring them to certify they have never led such projects. It defines "sex" biologically at birth (based on reproductive biology and genetics) and "minor" as anyone under 18. The law bans funding for any federally-supported research meeting these criteria, regardless of the study's focus.
This bill prohibits the Department of Health and Human Services from finalizing, implementing, or enforcing the proposed "Safe and Appropriate Foster Care Placement Requirements for Titles IV-E and IV-B" rule (published September 28, 2023). It directly affects federal foster care programs by blocking a specific rule that would have required states to consider religious beliefs when placing children in foster care. The key mechanism is a clear statutory ban on the rule's implementation, preventing it from taking effect. The bill does not create new requirements but stops the enforcement of this particular federal regulation.
The Maximum Pressure Act (HR 6114) is a legislative proposal that would maintain and expand U.S. sanctions against Iran. The bill would codify existing sanctions, require Iran to meet 12 specific conditions before sanctions could be lifted (including ending support for terrorism, releasing hostages, and ending nuclear enrichment), and expand sanctions on Iran's Revolutionary Guard Corps and missile programs. It also establishes new reporting requirements for the U.S. government to monitor Iran's activities and the impact of sanctions. The legislation would require congressional review before any sanctions could be lifted or modified, preventing the executive branch from unilaterally easing restrictions.
This bill establishes an Agricultural Trade Enforcement Task Force to address foreign trade barriers harming U.S. agricultural exports, specifically targeting India's WTO-violating price support programs for rice, wheat, and other commodities. The Task Force, led by the U.S. Trade Representative and Agriculture Department, must identify systemic trade barriers, develop enforcement strategies, and file a WTO dispute against India within 60 days of consultations if needed. It requires quarterly reports to Congress on progress, including a specific plan to challenge India's subsidies that exceed WTO limits (e.g., rice supports at 93.9% of production value). The bill directly affects U.S. farmers, ranchers, and exporters who face market access barriers due to these foreign subsidies.
HR 5737, the Elevating HSA Limits Act of 2023, increases the maximum annual contribution limits for Health Savings Accounts (HSAs) to match the deductible and out-of-pocket limits of qualifying high-deductible health insurance plans. This change directly affects individuals with HDHPs who use HSAs, as their annual contribution caps will now automatically adjust each year based on the current plan's deductible and out-of-pocket maximums instead of fixed 2023 dollar amounts. The bill amends the Internal Revenue Code to replace the current fixed limits ($2,250 for self-only coverage and $4,500 for family coverage) with a dynamic formula tied to plan costs. These changes apply to tax years beginning after December 31, 2023.
This bill amends tax code rules to allow married individuals to contribute to their own health flexible spending account (FSA) even if their spouse already has an FSA. It permits these contributions provided the combined reimbursements for both spouses do not exceed the total eligible expenses that would apply if the spouse's account didn't exist. The change applies to health savings plans starting in 2024, affecting married taxpayers with dual FSA coverage. It clarifies the reimbursement limits without creating new benefits or altering existing FSA structures.
The ORPHAN Cures Act amends the Drug Price Negotiation Program under the Social Security Act to clarify how orphan drugs (medications for rare diseases affecting fewer than 200,000 people in the U.S.) are treated. It ensures that periods when a drug was designated as an orphan drug are excluded from the time calculation used to determine when the drug can no longer be excluded from price negotiations. The bill also updates the definition to allow a single drug to be designated for multiple rare diseases, rather than just one. This change provides clearer rules for manufacturers and the government regarding orphan drug exclusions in the program.
The Maintaining Investments in New Innovation Act (HR 5547) extends the exclusivity period for certain advanced drugs from 7 to 11 years. It defines an "advanced drug product" as a drug using genetically targeted technology to change how genes work, such as drugs that suppress or activate gene function. The bill amends the Social Security Act to update the definition of "qualifying single source drug" to include these advanced therapies with the longer exclusivity period. This change directly affects drug manufacturers developing such advanced therapies and influences Medicare's drug coverage rules by delaying generic competition for these specific treatments.
